NL-OMON35874
Completed
Not Applicable
A Phase Ib, double-blind, randomized, placebo-controlled trial in genotype 1 HCV-infected patients to determine the safety, tolerability, pharmacokinetics and antiviral activity of repeated doses of TMC649128 given as monotherapy and given in combination with pegylated interferon + ribavirin - TMC649128/interferon/ribavirin in HCV patients
PRA International EDS0 sites30 target enrollmentTBD
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- hepatitis C
- Sponsor
- PRA International EDS
- Enrollment
- 30
- Status
- Completed
- Last Updated
- last year
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Hepatitis C infected patients
- •18\-65 year
- •BMI 18\.0 \- 35\.0 kg/m2
Exclusion Criteria
- •positive for Hepatitis B or HIV
- •except from hepatitis C infection diagnosed as not\-healthy
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Phase 1
A blinded study in healthy volunteers to evaluate the safety of the test medicine and compare how the test medicine behaves when the dosage is increased, and when taken alone or alongside salbutamol (albuterol)Cystic fibrosis (CF)Nutritional, Metabolic, EndocrineCystic fibrosisISRCTN30841680F. Hoffman-La Roche Ltd.41
Active, not recruiting
Phase 1
A study to evaluate safety and processing by body of GDC-6988 in healthy adults receiving albuterol as a pretreatment medicatioSafety and pharmacokinetics of multiple ascending doses of GDC-6988 with and without albuterol pretreatment in healthy adult subjectsNot ApplicableISRCTN15406513F. Hoffmann-La Roche Ltd30
Active, not recruiting
Not Applicable
A clinical trial of antibody GSK1070806 in the treatment of patients with moderate to severe Crohn’s diseaseISRCTN11093445niversity of Birmingham5
Completed
Not Applicable
A phase 1b, randomized, double-blinded, placebo-controlled study of hydroxychloroquine in outpatient adults with COVID-19CoronaCOVID-1910047438NL-OMON49040Sanofi-aventis20
Recruiting
Phase 2
A phase IIb, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of Astegolimab in patients with chronic obstructive pulmonary disease.J44 Other chronic obstructive pulmonary diseaseOther chronic obstructive pulmonary diseasePER-066-21GENENTECH, INC.23